Strong Demand for New Active Ingredients
Sales of new active ingredients nearly doubled compared to the prior year, demonstrating strong demand for technological innovations.
Adjusted EBITDA Improvement
Reported adjusted EBITDA of $236 million, 17% higher than prior year, driven by disciplined cost control and a favorable product mix.
Positive North America and EMEA Performance
Sales in North America and EMEA improved due to higher volumes and the launch of Isoflex active in Great Britain.